



ASX ANNOUNCEMENT

11 December 2024

Opyl Signs New Partnership Agreement with NeuOrphan

Melbourne, Australia – Opyl Limited (ASX: OPL) a leader in clinical trial design and biostatistical validation, is pleased to announce the signing of a Partnership Agreement with NeuOrphan Pty Ltd, a forward-thinking biotechnology company specialising in therapies for neurological disorders. This agreement follows the success of a transformative preliminary report that showcased the unparalleled capabilities of Opyl's TrialKey platform to deliver actionable insights and validate its leadership in the clinical trial optimisation market.

Key Highlights:

- **Strategic Partnership:** The agreement strengthens Opyl's collaboration with NeuOrphan Pty Ltd, a biotech leader focused on developing therapies for neurological disorders.
- **Proven Impact:** The decision follows a transformative preliminary report that validated TrialKey's ability to refine trial design and improve success probabilities.
- **Comprehensive Services:** Opyl will provide AI-powered reports offering predictive analytics, inclusion/exclusion criteria, and detailed competitor benchmarking.
- **Value-Driven Model:** Each report is priced at \$5,000 AUD, reflecting the platform's exceptional value in streamlining trials and accelerating development timelines.

Why NeuOrphan Chose TrialKey

The initial preliminary report provided by TrialKey offered NeuOrphan groundbreaking insights, setting a new standard for how trials are designed and executed. NeuOrphan was particularly impressed by:

- **Exceptional Predictive Modelling:** TrialKey's AI simulations de-risked trial design by identifying areas of improvement, ensuring increased probability of success.
- **Strategic Market Positioning:** Competitor benchmarking equipped NeuOrphan with the intelligence to position their trial effectively in a competitive space.
- **Precision Design Recommendations:** Insights into trial protocols, inclusion/exclusion criteria, and endpoint optimisation underpinned their confidence in future success.



These insights validated the transformational impact of TrialKey, paving the way for NeuOrphan to proceed with a full-scale collaboration.

Scope of Work

Under the Partnership Agreement, Opyl will deliver full-scale, AI-powered reports to support the advancement of NeuOrphan's novel therapies. The collaboration includes:

- **Comprehensive Trial Optimisation:** Leveraging predictive analytics to refine trial protocols, enhance site selection, and streamline participant engagement.
- **Data-Driven Visualisations:** Providing clear, actionable reporting for strategic decision-making and stakeholder communication.
- **Revenue Per Report:** With each report priced at \$5,000 AUD, the agreement reflects TrialKey's exceptional value and precision in transforming trial success rates.

Terms of Agreement

The agreement will continue until terminated with 30 days' written notice. During this period, Opyl will provide NeuOrphan with detailed reports and actionable insights for \$5,000 AUD per report. Both parties have committed to working collaboratively to ensure seamless integration of the TrialKey platform into NeuOrphan's operations.

Executive Commentary

Saurabh Jain, Executive Chair of Opyl, stated:

"TrialKey is not just a platform; it's a game-changer for clinical trials. NeuOrphan's decision to deepen this partnership is a testament to the unmatched quality and impact of our insights. By delivering highly actionable intelligence, we continue to redefine what's possible in clinical trial optimisation. This agreement not only demonstrates our ability to support groundbreaking research but also solidifies TrialKey's position as the market-leading AI solution for clinical research, pharmaceutical, and biotech communities."

Dr Steven Petratos, Co-Founder and Chief Scientific Officer of NeuOrphan, added:



"The preliminary report was a revelation—TrialKey delivered insights that were both precise and transformative. We're thrilled to expand this collaboration as we work to bring our therapies to patients faster and more efficiently. TrialKey empowers us to innovate with confidence, refining our trial strategies and addressing critical unmet needs in neurological care."

Driving Innovation Across Clinical Research

This agreement solidifies TrialKey's position as a transformative force in clinical research, equipping sponsors, clinical research organisations, and biotech innovators with cutting-edge tools to optimise trial design, enhance decision-making, and improve efficiency. By delivering unparalleled insights and fostering smarter processes, TrialKey is driving measurable advancements in trial outcomes. Its influence extends beyond individual projects, establishing Opyl as a pivotal partner in accelerating innovation across the pharmaceutical and biotech industries.

About NeuOrphan Pty Ltd

NeuOrphan Pty Ltd is a biotech innovator focused on developing therapies for multiple sclerosis and other neurological disorders. Their innovative drug candidate Dioprotectome™ aims to protect the central nervous system from inflammatory damage and promote repair through remyelination, addressing significant unmet medical needs.

This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice.averion@trialkey.ai

**About Opyl Limited (ASX: OPL)**

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.